Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody–Associated Diseases
COPANMO(G)-Study
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received September 16, 2022
- Accepted in final form November 16, 2022
- First Published January 24, 2023.
Author Disclosures
- Martin W. Hümmert, MD*,
- Franziska Bütow*,
- Daria Tkachenko, MD,
- Ilya Ayzenberg, MD,
- Thivya Pakeerathan,
- Kerstin Hellwig, MD,
- Luisa Klotz, MD,
- Vivien Häußler, MD,
- Jan-Patrick Stellmann, MD,
- Clemens Warnke, MD,
- Yasemin Goereci, MD,
- Thorleif Etgen, MD,
- Felix Luessi, MD,
- Paul Bronzlik, MD,
- Stefan Gingele, MD,
- Ann-Sophie Lauenstein, MD,
- Ingo Kleiter, MD,
- Paulus S. Rommer, MD,
- Friedemann Paul, MD,
- Judith Bellmann-Strobl, MD,
- Ankelien Duchow, MD,
- Florian Then Bergh, MD,
- Refik Pul, MD,
- Annette Walter, MD,
- Hannah Pellkofer, MD,
- Tania Kümpfel, MD,
- Mosche Pompsch, MD,
- Markus Kraemer, MD,
- Philipp Albrecht,
- Orhan Aktas, MD,
- Marius Ringelstein, MD,
- Makbule Senel, MD,
- Katrin Giglhuber, MD,
- Achim Berthele, MD,
- Sven Jarius, MD,
- Brigitte Wildemann, MD and
- Corinna Trebst, MD on behalf of Neuromyelitis Optica Study Group (NEMOS)
- Martin W. Hümmert, MD*,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
The NEMOS cohort/NationNMO is supported by the German Ministry for Education and Research (BMBF) as part of the German Competence Network Multiple Sclerosis (KKNMS).
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Franziska Bütow*,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
The NEMOS cohort/NationNMO is supported by the German Ministry for Education and Research (BMBF) as part of the German Competence Network Multiple Sclerosis (KKNMS)
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Daria Tkachenko, MD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Ilya Ayzenberg, MD,
Roche, Alexion, Merck, Horizon, Sanofi Aventis
NONE
Roche, Alexion, Merck, Horizon, Sanofi Aventis
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Diamed
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Thivya Pakeerathan,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Kerstin Hellwig, MD,
(1) Novartis (2) Genzyme (3) Teva (4) Merck (5) Roche (6) Jansen
NONE
(1) Biogen, funding for travel (2) Novartis, funding for travel (3) Merck, funding for travel (4) Biogen Idec Germany, speaker honoraria (5) Teva, speaker honoraria (6) Sanofi Genzyme, speaker honoraria (7) Novartis, speaker honoraria (8) Bayer Healthcare, speaker honoraria (9) Merck Serono, speaker honoraria (10) Roche, speaker honoraria (11) BMS, speaker honoraria (12) Jansen, speaker honoraria
Editorial board N2 journal TAND associate editor
NONE
NONE
NONE
NONE
Honoraria from Biogen, Bayer Healthcare, Teva, Sanofi, Merck, BMS, Jansen and Novartis
NONE
NONE
Almiral, Biogen, Bayer Healthcare, Teva, Merck, Roche, Sanofi- Genzyme and Novartis
(1) Fund of the Federal Joint Committee
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Luisa Klotz, MD,
(1) Genzyme (2) Novartis (3) Roche (4) Merck (5) Janssen (6) Alexion (7) Celgene (8) Horizon (9) Viatris
NONE
(1) Novartis, speaker honoraria and travel support (2) Merck Serono, speaker honoraria and travel support (3) Biogen, speaker honoraria and travel support (4) Roche, speaker honoraria and travel support (5) Genzyme, speaker honoraria and travel support (6) Teva, speaker honoraria and travel support (7) Janssen, speaker honoraria and travel support (8) Santhera, speaker honoraria and travel support (9) Grifols, speaker honoraria and travel support (10) Alexion, speaker honoraria and travel support (11) Bayer, speaker honoraria and travel support (12) Celgene, speaker honoraria and travel support
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Novartis (2) Biogen (3) Merck (4) Immunic AG
(1) (CRC) SFB TR-128 Impact of dietary factors on the gut-CNS-axis implications for CNS autoimmunity A08, Project leader, 2020-2024 (2) (CRC) SFB 1009 Immune-cell interactions with endothelial cells and pericytes at the blood-brain- barrier: mechanisms and consequences A03, Sub-project Leader, 2020-2024 (3) DFG, KFO 342
Interdisciplinary Centre for Clinical Research, Münster (IZKF) Innovative medizinische Forschung (IMF)
None
NONE
NONE
NONE
NONE
NONE
NONE
- Vivien Häußler, MD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Jan-Patrick Stellmann, MD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
BMBF, German competence Network Multiple sclerosis (KKNMs). (FKZ 01GI1602c) 2016-2019
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Clemens Warnke, MD,
Biogen, Novartis, Roche, Janssen, Merck; institutional fees only.
NONE
Speakers honoraria Novartis, Biogen, Bayer, Genzyme, Alexion. Institutional fees only.
Frontiers in Neurology, associate editor, 2016
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Novartis,Biogen, Roche. Institutional fees only.
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Yasemin Goereci, MD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Thorleif Etgen, MD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Felix Luessi, MD,
advisory board member for Roche Pharma
NONE
travel funding from Teva Pharma
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Paul Bronzlik, MD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Stefan Gingele, MD,
Alnylam pharmaceuticals.
NONE
Alnylam pharmaceuticals, speaker honoraria. Merck, speaker honoraria.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Hannover Biomedical Research School (HBRS)
German Research Foundation, Else Kröner Fresenius Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Ann-Sophie Lauenstein, MD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Ingo Kleiter, MD,
None
NONE
Alexion, Biogen, Celgene, Horizon, Merck, Roche
BMC Neurology, associate editor, since 2018 Neuroimmunology Reports, editorial board member, since 2020 Frontiers in Neurology, associate editor, since 2022 Frontiers in immunology, associate editor, since 2022
NONE
NONE
NONE
Alexion, Almirall, Biogen, Celgene, Hexal, Horizon, Merck, Roche
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Paulus S. Rommer, MD,
1) Sandoz 2) Merck
NONE
1) Alexion, speaker honoraria (sh) 2) Roche, sh 3) Sanofi, sh 4) Sandoz, sh 5) Amicus, sh 6) Horizon, sh 7) allmiral, sh 8) Merck, sh
Associate Editor : Frontiers in Neurology, Frontiers in Immunology
NONE
NONE
NONE
1) Alexion 2) Roche 3) Merck 4) Sanofi 5) Sandoz 6) Novartis 7) Horizon 6) Horizon
1) Almirall, Alexion, Biogen, Merck, Sanofi, Amicus
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Friedemann Paul, MD,
Novartis OCTIMS study steering committee MedImmune / Viela Bio steering committee
NONE
speaker honoraria and travel grants from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, and Merck Serono, Alexion, Chugai, MedImmune, Shire, Roche, Actelion, Celgene
Academic Editor, PLoS ONE Associate Editor, Neurology Neuroimmunology and Neuroinflammation
NONE
NONE
NONE
consultancies for SanofiGenzyme, BiogenIdec, MedImmune, Shire, Alexion, Hoffmann-La Roche, Celegene, Horizon Therapeutics, Merck, Neurogenesis Ltd.
NONE
NONE
NONE
Research support from from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, Alexion and Merck Serono
German Research Council (DFG Exc 257), Werth Stiftung of the City of Cologne, German Ministry of Education and Research (BMBF Competence Network Multiple Sclerosis), Arthur Arnstein Stiftung Berlin, EU FP7 Framework Program (combims.eu)
NONE
rthur Arnstein Foundation Berlin, Guthy Jackson Charitable Foundation, National Multiple Sclerosis Society of the USA
NONE
NONE
NONE
NONE
NONE
NONE
- Judith Bellmann-Strobl, MD,
None
NONE
Travel grants and speaking honoraria from Merck Serono, Sanofi Genzyme, Horizone, Fa. Hoffmann-La Roche and Novartis, none of them related to preparing this manuscript.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Ankelien Duchow, MD,
None
NONE
(1) Roche,speaker honorarium
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Florian Then Bergh, MD,
Speaker honoraria and consultancy fees as a speaker and advisor from Actelion, Bayer Healthcare, Biogen, Merck Serono, Novartis, Roche, Sanofi Genzyme, and TEVA.
NONE
Support to attend scientific meetings from Bayer Schering, Biogen, Merck, Novartis and Sanofi-Genzyme.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Support for investigator-initiated trials from Actelion, Novartis. Travel support to present results at scientific meetings, through the employing institution, from Bayer Schering, Biogen, Merck, Novartis and Sanofi Genzyme.
German Federal Ministry of Research; Deutsche Forschungsgemeinschaft (DFG, federal research funding agency)
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Refik Pul, MD,
(1) Alexion (2) Biogen (3) Celgene/BMS (4) Horizon (5) Merck (6) Mylan (7) Novartis (8) Roche (9) Sanofi
NONE
(1) Alexion, speaker honoraria (2) Biogen, speaker honararia (3) Celgene/BMS, funding for travel to congress, speaker honoraria (4) Horizon, funding for travel to congress, funding for research, speaker honoraria (5) Merck, funding for travel to congress, funding for research, speaker honoraria (6) Mylan, funding for travel to congress, speaker honararia (7) Novartis, funding for research, speaker honoraria (8) Roche, speaker honararia (9) Sanofi-Genzyme, speaker honoraria
Guest Editor in Frontiers in Neurology Guest Editor in Cells
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Merck (2) Novartis
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Annette Walter, MD,
1.) Sanofi 2.) Novartis 3.) Roche
NONE
1.) Genzyme: Honoraria for speaking engagements 2.) Novartis: Honoraria for speaking engagements 3.) Novartis: Costs of congress participation including travel costs and Hotel 4.) Merck: Costs of congress participation including travel costs and Hotel 5.) Bayer: Costs of congress participation including travel costs and Hotel
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Hannah Pellkofer, MD,
(1) Roche, Advisory board
NONE
(1) Biogen, Speakers honoraria
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Tania Kümpfel, MD,
T. Kümpfel has served on advisory boards for Merck, Roche Pharma, Biogen, Chugai and for Alexion
NONE
T. Kümpfel has received personal compensations/speaker honoraria from Alexion/Astra Zeneca, Roche Pharma and Horizon
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Mosche Pompsch, MD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Markus Kraemer, MD,
None
NONE
;MK received honoraria for educational activities from Roche Pharma and Chugai Pharma.
Associate Editor of German DGNeurologie Journal.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Philipp Albrecht,
(1) Novartis, serving on an advisory board; (2) Biogen, serving on an advisory board; (3) Ipsen, serving on an advisory board; (4) Merck, serving on an advisory board; (5) Merz, serving on an advisory board; (6) Roche, serving on an advisory board; (7) Allergan, serving on an advisory board; (8) Celgene, serving on an advisory board; (9) Janssen Cilag, serving on an advisory board
NONE
(1) Novartis, travel/accommodation/meeting expenses and speaker honoraria; (2)Teva, travel/accommodation/meeting expenses and speaker honoraria; (3) Biogen, travel/accommodation/meeting expenses and speaker honoraria; (4) Merz Pharmaceuticals, travel/accommodation/meeting expenses, (5) Ipsen, travel/accommodation/meeting expenses; (6) Esai, travel/accommodation/meeting expenses; (7) Glaxo Smith Kline, travel/accommodation/meeting expenses; (8) Bayer Healthcare, speaker honoraria, travel/accommodation/meeting expenses; (9) Allergan, speaker honoraria, travel/accommodation/meeting expenses; (10) Celgene, travel/accommodation/meeting expenses; (11) (9) Merck, speaker honoraria, travel/accommodation/meeting expenses; (12) Bristol Meyers Squibb
(1) BMC Neuroscience, associate editor (2) Frontiers in Neurology, associate editor (3) Journal of Clinical Medicine, associate editor (4) Frontiers in Immunology, associate editor
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Biogen (2) Novartis (3) Merz Pharmaceuticals (4) Ipsen (5) Roche (6) Allergan (7) Celgene
European Fund For Regional Development (EFRE.NRW)
NONE
(1) Doktor Robert Pfleger Stiftung (2) Iselore Luckow Stiftung (3) Europäischer Fonds für Forschung und Regionale Entwicklung (EFRE)
NONE
NONE
NONE
NONE
NONE
NONE
- Orhan Aktas, MD,
None
NONE
(1) Bayer, speaker honoraria (2) Novartis, speaker honoraria (3) Biogen, travel and speaker honoraria (4) Merck Serono, travel and speaker honoraria (5) Teva, speaker honoraria (6) Sanofi-Genzyme, speaker honoraria (7) Roche, travel and speaker honoraria (8) Almirall, travel and speaker honoraria (9) Alexion, travel and speaker honoraria (10) Celgene, travel and speaker honoraria (11) Viela Bio, travel support (12) Horizon, travel and speaker honoraria
(1) PLoS ONE, Academic Editor, since 2012
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Biogen
(1) German Ministry of Science (BMBF), PI for NationNMO/KKNMS (NationNMO‐PAT FKZ 01GI1602B), 2016 - 2021
(1) German Research Foundation (DFG), PI in GRK2578, since 2020
None
NONE
NONE
NONE
NONE
NONE
NONE
- Marius Ringelstein, MD,
1. Roche Pharma GmbH, served on a national scientific advisory board. 2. Alexion Pharma GmbH, served on a national scientific advisory board.
NONE
1. Alexion, speaking honorarium. 2. Roche,speaking honorarium and funding for travel to a conference. 3. Biogen Idec, funding for travel to a conference.
NONE
NONE
NONE
NONE
1. Roche Pharma GmbH, served on a national and international scientific advisory board. 2. Alexion Pharma GmbH, served on a national scientific advisory board.
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Makbule Senel, MD,
MS has received consulting and/or speaker honoraria from Alexion, Bayer, Biogen, Merck, Roche, and Sanofi Genzyme. She has received research funding from the Hertha-Nathorff- Program.
NONE
She has received travel funding from Celgene, and TEVA.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Katrin Giglhuber, MD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Achim Berthele, MD,
(1) Alexion Pharma (2) Biogen (3) Celgene (4) Roche Pharma (5) Hexal/Novartis
NONE
(1) Alexion Pharma, funding for travel and speaker honoraria (2) Bayer Healthcare, speaker honoraria (3) Biogen, speaker honoraria (4) Roche Pharma, funding for travel and speaker honoraria.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Sven Jarius, MD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Brigitte Wildemann, MD and
None
NONE
Brigitte Wildemann has received personal fees from Alexion, Bayer, Biogen, Roche
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
rigitte Wildemann reports grants from Deutsche Forschungsgemeinschaft, Bundesministerium für Forschung und Technologie, grants from Dietmar Hopp Stiftung, grants from Klaus Tschira Stiftung, grants from Merck
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Corinna Trebst, MD on behalf of Neuromyelitis Optica Study Group (NEMOS)
None
NONE
Speaker honoraria (educational efforts, CME activities) from Alexion Pharma Germany GmbH and Roche Pharma GmbH.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (M.W.H., F.B., D.T., S.G., C.T.), Hannover Medical School, Germany; Department of Neurology (I.A., T.P., K.H., I.K.), St. Josef Hospital, Ruhr University Bochum, Germany; Department of Neurology (L.K.), University of Münster, Germany; Department of Neurology and Institute of Neuroimmunology and MS (INIMS) (V.H., J.-P.S.), University Medical Center Hamburg-Eppendorf, Germany; Aix-Marseille Univ (J.-P.S.), CNRS, CRMBM, UMR 7339, Marseille Cedex, France; APHM (J.-P.S.), Hopital de La Timone, CEMEREM, Marseille, France; Department of Neurology (C.W., Y.G.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany; Department of Neurology (T.E.), Kliniken Südostbayern-Klinikum Traunstein, Germany; Department of Neurology (F.L.), University Medical Center of the Johannes Gutenberg University Mainz, Germany; Hannover Medical School (P.B.), Department of Diagnostic and Interventional Neuroradiology, Germany; Department of Neurology (A.-S.L.), German Diagnostic Clinic, DKD Helios Clinic Wiesbaden, Germany; Marianne-Strauß-Klinik (I.K.), Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke, Berg, Germany; Department of Neurology (P.S.R.), Medical University of Vienna, Austria; Experimental and Clinical Research Center (F.P., J.B.-S., A.D.), a Cooperation Between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité Universitätsmedizin Berlin, Germany; Department of Neurology (F.P., J.B.-S., A.D.), Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Experimental and Clinical Research Center, Germany; Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) (F.P., J.B.-S., A.D.), Berlin, Germany; Department of Neurology (F.T.B.), University of Leipzig, Germany; Department of Neurology (R.P.), University of Essen, Germany; Department of Neurology (A.W.), Herford Hospital, Germany; Institute of Clinical Neuroimmunology (H.P., T.K.), LMU Hospital, Ludwig-Maximilians Universität München, Germany; Department of Neurology (M.P., M.K.), Alfried-Krupp-Krankenhaus Essen, Germany; Department of Neurology (M.K., P.A., O.A., M.R.), Medical Faculty, Heinrich Heine University Düsseldorf, Germany; Department of Neurology (M.R.), Center for Neurology and Neuropsychiatry, LVR-Klinikum, Heinrich Heine University Düsseldorf, Germany; Department of Neurology (M.S.), University of Ulm, Germany; Department of Neurology (K.G., A.B.), School of Medicine, Technical University Munich, Klinikum Rechts der Isar, Germany; and Molecular Neuroimmunology Group (S.J., B.W.), Department of Neurology, University of Heidelberg, Germany.
- Correspondence
Dr. Trebst trebst.corinna{at}mh-hannover.de
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Babak Hooshmand and Dr. David Smith
► Watch
Related Articles
- No related articles found.